Quick Takeaways
- David E. Lazar filed SCHEDULE 13D/A for Cyclacel Pharmaceuticals, Inc. Common Stock, $0.001 par value (CYCC).
- Disclosed ownership: 8.2%.
- Date of event: 30 Jul 2025.
David E. Lazar - 30 Jul 2025 SCHEDULE 13D/A Report for Cyclacel Pharmaceuticals, Inc. Common Stock, $0.001 par value (CYCC)
- Filing Manager
- David E. Lazar
- Reporting Manager
- Lazar David E.
- Symbol
- CYCC
- Shares outstanding
- 1,584,707 shares
- Disclosed Ownership
- 129,629 shares
- Ownership
- 8.2%
- Form type
- SCHEDULE 13D/A
- Filing time
- 04 Aug 2025, 19:24:57 UTC
- Date of event
- 30 Jul 2025
- Previous filing
- 28 Feb 2025
- Next filing
- 08 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"David E. Lazar disclosed 8.2% ownership in Cyclacel Pharmaceuticals, Inc. Common Stock, $0.001 par value (CYCC) on 30 Jul 2025."
What Changed
- Previous schedule filing date: 28 Feb 2025.
- Current filing was accepted on 04 Aug 2025, 19:24.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Lazar David E. | 8.2% | 129,629 | 129,629 | 0 | /s/ David E. Lazar | David E. Lazar | 0001932843 |